Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Chemomab Therapeutics Ltd ADR’s stock clocked out at $1.90, down -1.55% from its previous closing price of $1.93. In other words, the price has decreased by -$1.55 from its previous closing price. On the day, 14.55 million shares were traded.
Ratios:
To gain a deeper understanding of CMMB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.57 and its Current Ratio is at 4.57. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on May 13, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On May 06, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 12 ’24 when OrbiMed Israel Partners Limite bought 500,000 shares for $2.03 per share.
Stock Price History:
Over the past 52 weeks, CMMB has reached a high of $2.55, while it has fallen to a 52-week low of $0.55. The 50-Day Moving Average of the stock is -2.22%, while the 200-Day Moving Average is calculated to be 28.96%.
Shares Statistics:
A total of 18.86M shares are outstanding, with a floating share count of 16.57M. Insiders hold about 12.13% of the company’s shares, while institutions hold 12.87% stake in the company.
